Latest Breaking News On - Fast track designation - Page 10 : comparemela.com

Theriva Biologics (TOVX) Announces Fast Track Designation Granted by the U S FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva Biologics (TOVX) Announces Fast Track Designation Granted by the U S FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTheriva biologicsStevena shallcrossDrug administrationFast track designationChief executive officer

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy.

United statesMccormick placeTheodore jenkinsLeslyem heislerKyle evansCharu aggarwalCompany nasdaqBusiness developmentExchange commissionAmerican society of clinical oncologyPerelman school of medicineDrug administrationUniversity of pennsylvaniaMccormick place convention centerCandel therapeutics incClinical oncology

Bicycle Therapeutics plc: Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational

United statesUnited kingdomFrance generalGustave roussyYohann loriotJustin baderKevin leeDeborah elsonStephanie yaoExchange commissionInternational nonproprietary nameDrug administrationCorporate communicationsAmerican society for clinical oncologyBicycle toxinBicycle toxin conjugate

Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

23.05.2024 - Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that emerging Phase 1/2 clinical . Seite 1

United statesKevin leeDrug administrationAmerican society for clinical oncologyInternational nonproprietary nameBicycle therapeuticsBicycle toxin conjugatesClinical oncologyAnnual meetingFast track designationTrack designationSafety dataBicycle toxinSession titleDevelopmental therapeuticsMolecularly targeted agents

Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON (BUSINESS WIRE) May 23, 2024

United statesFrance generalUnited kingdomGustave roussyJustin baderKevin leeYohann loriotStephanie yaoDeborah elsonDrug administrationAmerican society for clinical oncologyCorporate communicationsInternational nonproprietary nameExchange commissionBicycle toxin conjugatesClinical oncology